[Which antidiabetic agent in a patient with type 2 diabetes and heart failure ?]

Area of Science:

• Cardiology
• Endocrinology
• Pharmacology

Background:

• Type 2 diabetes (T2D) is increasingly linked to heart failure (HF).
• Patients with T2D often have multiple risk factors for HF and longer survival allows for its development.
• Improved prevention of atherothrombotic events contributes to longer survival, increasing HF incidence in T2D patients.

Observation:

• Glucose-lowering agents have varying impacts on HF risk.
• Some agents are associated with a reduced risk of HF hospitalization.
• Other agents are linked to a proven or suspected increased risk of HF.

Findings:

• The choice of glucose-lowering drugs is critical in managing T2D patients with or at risk of HF.
• Differential effects of glucose-lowering drugs on HF outcomes necessitate careful selection.
• Clinical decisions must consider the HF risk profile associated with specific antihyperglycemic therapies.

Implications:

• Optimizing glucose-lowering therapy can mitigate HF risk in T2D.
• Clinicians must individualize treatment strategies based on HF risk.
• Further research into HF-specific outcomes of glucose-lowering drugs is warranted.